# MDT Discussion Log — 2026-01-21_08-11-31
Generated automatically by MDT Pipeline.



## CASE (structured JSON)

```
{"CASE_CORE":{"ADJUVANT_TREATMENT":{"cycles_or_courses":"6","given":"Yes","regimens":["白紫+卡铂"]},"BIOMARKERS":{"AFP":"<0.91 ng/ml (2022-10-12)","CA125":"933.00 U/ml (2022-12-29)","HER2":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","TMB":"Unknown"},"BRCA1":"Unknown","BRCA2":"Unknown","CURRENT_STATUS":"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging","DIAGNOSIS":{"components":["High-grade adenocarcinoma involving full-thickness intestinal wall","Lymph node metastasis (4/15)","Peritoneal/rectal/vaginal involvement described"],"histology":"透明细胞癌; 肠壁全层见高级别腺癌","laterality":"Unknown","primary":"卵巢癌复发","site":"Ovary"},"HRD":"Unknown","INITIAL_TREATMENT":"Unknown","LINE_OF_THERAPY":[{"cycles":"6","end_date":"2022-08-17","intent":"Unknown","line":"1L","regimen":"白紫+卡铂","start_date":"Unknown"}],"MAINTENANCE":"Unknown","MAINTENANCE_DETAIL":{"end_date":"Unknown","given":"Unknown","regimens":[],"start_date":"Unknown"},"NEOADJUVANT":"Unknown","PFI_days":"56","PLATINUM_HISTORY":[{"PFI_days":"56","end_date":"2022-08-17","evidence":"Rise in CA125/CA19-9 on 2022-10-12","evidence_type":"Biochemical","first_relapse_date":"2022-10-12","line":"1L","start_date":"Unknown","status":"Resistant"}],"PLATINUM_PFI_CURRENT":"56","PLATINUM_STATUS":"Resistant","PLATINUM_STATUS_CURRENT":"Resistant","RELAPSE":"Yes","RELAPSE_DATE":{"date":"2022-10-12","evidence":"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence","type":"Biochemical"},"SCENE":"Platinum_resistant_relapse","STAGE":{"stage_basis":"Unknown","stage_system":"Unknown","stage_text":"Unknown"},"SURGERY_DONE":{"date":"2022-03-28","performed":"Yes","procedure":"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair"},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]},"VISIT_DATE":"2023-01-03","first_relapse_date":"2022-10-12","last_platinum_end_date":"2022-08-17"},"LAB_TRENDS":{"labs":[{"analyte":"CA125","history":[{"date":"2022-08-15","flag":"Unknown","value":"14.90"},{"date":"2022-10-12","flag":"↑","value":"89.60"},{"date":"2022-11-17","flag":"↑","value":"403"},{"date":"2022-12-29","flag":"↑","value":"933.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"933.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"CA19-9","history":[{"date":"2022-08-15","flag":"Unknown","value":"7.16"},{"date":"2022-10-12","flag":"↑","value":"77.20"},{"date":"2022-12-29","flag":"↑","value":"229.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"229.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"HE4","history":[{"date":"2022-08-15","flag":"↑","value":"87.90"},{"date":"2022-10-12","flag":"Unknown","value":"59.70"},{"date":"2022-12-29","flag":"↑","value":"111.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"111.00"},"reference_range":"Unknown","unit":"pmol/L"},{"analyte":"AFP","history":[{"date":"2022-10-12","flag":"Unknown","value":"<0.91"}],"latest":{"date":"2022-10-12","flag":"Unknown","value":"<0.91"},"reference_range":"Unknown","unit":"ng/ml"}],"milestones":[{"date":"2022-03-28","description":"Primary cytoreductive surgery performed","type":"Surgery"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂","type":"ChemoEnd"},{"date":"2022-10-12","description":"Biochemical relapse with rising tumor markers","type":"Relapse"}]},"MED_ONC":{"current_regimen":{"cycle_info":"6 cycles of 白紫+卡铂, last 2022-08-17","last_admin_date":"2022-08-17","name":"Unknown"},"genetic_testing":{"germline":[],"somatic":[]},"monitoring_points":[],"planned_next_regimen":"Unknown","prior_systemic_therapies":["白紫+卡铂"]},"NUC_MED":{"studies":[]},"PATHOLOGY":{"specimens":[{"components":["Tumor size ~7x4x2.5 cm","Bilateral margins negative","Pericolic lymph nodes 4/15 positive","One tumor nodule (posterior bladder)"],"date":"2022-03-28","diagnosis":"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma","grade":"High-grade","ihc":[{"marker":"MLH1","result":"+"},{"marker":"MSH6","result":"+"},{"marker":"MSH2","result":"+"},{"marker":"PMS2","result":"+"},{"marker":"ER","result":"partial+"},{"marker":"PR","result":"few weak+"},{"marker":"P53","result":"+/-"},{"marker":"WT1","result":"-"},{"marker":"Ki-67","result":"60%+"},{"marker":"HNF1B","result":"+"},{"marker":"NapsinA","result":"focal+"},{"marker":"P16","result":"+"},{"marker":"PAX8","result":"+"},{"marker":"SALL4","result":"-"},{"marker":"ZBTB16","result":"-"}],"involvement_sites":["Rectosigmoid colon","Left retroperitoneum","Vagina","Pericolic lymph nodes","Posterior bladder nodule"],"laterality":"Unknown","molecular":[],"raw_text":"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）","sample_type":"Surgical resection","site":"Partial rectosigmoid + left retroperitoneal tumor + partial vagina","tumor_size":"7 x 4 x 2.5 cm","uncertainty_or_missing":["BRCA/HRD testing not reported"]}]},"RADIOLOGY":{"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"},"studies":[{"anatomic_sites":["Pelvis"],"date":"2022-10-24","findings":["Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules"],"impression":"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases","modality":"MRI","trend_vs_prior":"Unknown"},{"anatomic_sites":["Liver"],"date":"2022-10-25","findings":["Multiple intrahepatic nodules, some new compared to prior"],"impression":"Probable metastases in liver","modality":"CT","trend_vs_prior":"Worse"},{"anatomic_sites":["Pelvis; sacrum; right iliac bone"],"date":"2022-12-30","findings":["Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar"],"impression":"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible","modality":"MRI","trend_vs_prior":"Worse"},{"anatomic_sites":["Liver; spleen"],"date":"2022-12-30","findings":["Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct"],"impression":"Progression of hepatic metastases","modality":"CT","trend_vs_prior":"Worse"}]},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]}}
```


## FINAL MDT OUTPUT

```
Final Assessment:
Platinum-resistant recurrent clear cell carcinoma (HRD-negative, pMMR) presenting with severe anemia and disseminated metastases including presacral mass with rectal invasion. Systemic therapy options are limited by platinum resistance and contraindication to anti-angiogenics due to high bowel perforation risk.

Core Treatment Strategy:
- Transfuse immediately for severe anemia (Hb 74 g/L) to permit safe systemic therapy [@20230103|5600862 | LAB].
- Initiate non-platinum chemotherapy; strictly avoid anti-angiogenics due to rectal invasion [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], [@2022-12-29|MR | MR].
- Refer for palliative radiotherapy evaluation targeting progressive presacral mass and bone metastases [@2022-12-29|MR | MR].
- Consider enrollment in Phase Ib/II trial for recurrent gynecologic malignancies as alternative to standard chemo [@trial | 350].

Change Triggers:
- If splenic infarct symptoms arise, evaluate for anticoagulation versus supportive care [@2022-12-29|CT | CT].
- If progression occurs on non-platinum regimen, transition to best supportive care or early-phase trials.

---
## References

### Guidelines

[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]
  Document: nccn_ovariancancer_v3_2025__v00000000, Page 22
  Content: Survivorship)
Recurrent
diseaset
Hormonal...

### Literature

### Clinical Trials

[@trial | 350]
  Trial ID: 350
  Name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
  Rationale: Patient has recurrent platinum-resistant ovarian clear cell carcinoma (a gynecologic malignancy) and has failed standard chemotherapy (1L), matching the inclusion criteria.

### Clinical Reports

[@20230103|5600862 | LAB]
  LAB ID: 20230103|5600862 | Date: 2023-01-03
  Content: 中性粒细胞% 76.5 % (GRAN) PLT分布宽度 12 % (PDW) 嗜碱性细胞数 0.01 *10^9/L...

[@2022-12-29|MR | MR]
  MR ID: 2022-12-29|MR | Date: 2022-12-29
  Content: 对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不...

[@2022-12-29|CT | CT]
  CT ID: 2022-12-29|CT | Date: 2022-12-29
  Content: 对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见...

```


## PIPELINE FLOW (Mermaid)

```mermaid
flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]
```


## TRACE EVENTS (Structured)

```json
[
  {
    "ts": "2026-01-21T08:00:14.260722",
    "event": "pipeline_start",
    "payload": {
      "visit_time": "2023-01-03 08:53:29.260000",
      "meta_info": "340123197709263626"
    }
  },
  {
    "ts": "2026-01-21T08:00:14.261284",
    "event": "case_fingerprint",
    "payload": {
      "case_fingerprint": "2a31f255c155"
    }
  },
  {
    "ts": "2026-01-21T08:00:14.535304",
    "event": "reports_loaded",
    "payload": {
      "lab_n": 92,
      "img_n": 10,
      "path_n": 0,
      "mut_n": 1,
      "cutoff_dt": "2023-01-04 08:53:29"
    }
  },
  {
    "ts": "2026-01-21T08:00:56.829790",
    "event": "reports_selected",
    "payload": {
      "lab": {
        "chair": [
          "20221229|8300002|2022-12-29",
          "20221229|9703212|2022-12-29",
          "20230103|5600862|2023-01-03"
        ],
        "oncologist": [
          "20221229|8300002|2022-12-29",
          "20221229|9703212|2022-12-29",
          "20230103|5600862|2023-01-03"
        ],
        "radiologist": [],
        "pathologist": [],
        "nuclear": []
      },
      "imaging": {
        "chair": [
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ],
        "oncologist": [],
        "radiologist": [
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ],
        "pathologist": [],
        "nuclear": [
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ]
      },
      "pathology": {
        "chair": [],
        "oncologist": [],
        "radiologist": [],
        "pathologist": [],
        "nuclear": []
      },
      "mutation": {
        "chair": [
          "OH2203828|2022-04-18"
        ],
        "oncologist": [
          "OH2203828|2022-04-18"
        ],
        "radiologist": [],
        "pathologist": [
          "OH2203828|2022-04-18"
        ],
        "nuclear": []
      }
    }
  },
  {
    "ts": "2026-01-21T08:00:56.835540",
    "event": "rag_key_facts",
    "payload": {
      "facts": "DIAGNOSIS: primary=卵巢癌复发; histology=透明细胞癌; 肠壁全层见高级别腺癌; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=<0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）"
    }
  },
  {
    "ts": "2026-01-21T08:01:45.772408",
    "event": "rag_query",
    "payload": {
      "query": "Platinum-resistant ovarian clear cell carcinoma with liver, presacral, and bone metastases; BRCA/HRD-negative, MSS, and germline ATM mutation; histology: clear cell carcinoma"
    }
  },
  {
    "ts": "2026-01-21T08:01:45.772419",
    "event": "rag_hits",
    "payload": {
      "source": "guideline",
      "topk": 5,
      "n": 5
    }
  },
  {
    "ts": "2026-01-21T08:01:45.772420",
    "event": "rag_hits",
    "payload": {
      "source": "pubmed",
      "topk": 5,
      "n": 0
    }
  },
  {
    "ts": "2026-01-21T08:01:45.772422",
    "event": "rag_hits_merged",
    "payload": {
      "n": 5
    }
  },
  {
    "ts": "2026-01-21T08:02:18.393724",
    "event": "mdt_discussion_start",
    "payload": {
      "num_rounds": 2,
      "num_turns": 2
    }
  },
  {
    "ts": "2026-01-21T08:02:18.393799",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "chair",
      "order": 1
    }
  },
  {
    "ts": "2026-01-21T08:02:50.635186",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "chair",
      "chars": 542
    }
  },
  {
    "ts": "2026-01-21T08:02:50.635274",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "oncologist",
      "order": 2
    }
  },
  {
    "ts": "2026-01-21T08:03:19.911102",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "oncologist",
      "chars": 535
    }
  },
  {
    "ts": "2026-01-21T08:03:19.911192",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "radiologist",
      "order": 3
    }
  },
  {
    "ts": "2026-01-21T08:03:46.791644",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "radiologist",
      "chars": 546
    }
  },
  {
    "ts": "2026-01-21T08:03:46.791714",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "pathologist",
      "order": 4
    }
  },
  {
    "ts": "2026-01-21T08:04:26.648356",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "pathologist",
      "chars": 476
    }
  },
  {
    "ts": "2026-01-21T08:04:26.648420",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "nuclear",
      "order": 5
    }
  },
  {
    "ts": "2026-01-21T08:05:29.524203",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "nuclear",
      "chars": 474
    }
  },
  {
    "ts": "2026-01-21T08:10:11.848602",
    "event": "mdt_discussion_end",
    "payload": {
      "merged_chars": 1200
    }
  },
  {
    "ts": "2026-01-21T08:10:11.850720",
    "event": "trial_matching_start",
    "payload": {
      "trials_json_path": "files/all_trials_filtered.json"
    }
  },
  {
    "ts": "2026-01-21T08:10:53.938125",
    "event": "trial_matching_end",
    "payload": {
      "recommended": true
    }
  },
  {
    "ts": "2026-01-21T08:10:53.938147",
    "event": "final_output_start",
    "payload": {}
  },
  {
    "ts": "2026-01-21T08:11:31.406269",
    "event": "final_output_end",
    "payload": {
      "final_output_chars": 2132
    }
  }
]
```


## INITIAL EXPERT OPINIONS


## chair

```
Here is the initial MDT assessment for the visit on 2023-01-03:

*   Platinum-resistant recurrence (PFI ~2 months); recommend non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
*   Correct significant anemia (Hb 74 g/L) prior to systemic therapy initiation to ensure safety [@20230103|5600862 | LAB].
*   BRCA/HRD negative status limits targeted options; consider palliative radiation for progressive bone metastases [@OH2203828 | Genomics], [@2022-12-29 | MR].
```


## oncologist

```
Based on the recurrence timing and biomarker profile:

- Platinum-resistant recurrence (PFI <6 months) confirmed by rising CA125 933 U/ml and multi-site metastases [@20221229|9703212 | LAB].
- Genomic profiling indicates HRD negative and BRCA wild-type status, limiting PARP inhibitor utility [@OH2203828 | Genomics].
- Consider non-platinum chemotherapy +/- anti-angiogenics; significant anemia (HGB 74 g/L) warrants correction prior to treatment [@20230103|5600862 | LAB] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
```


## radiologist

```
Here are the imaging findings for the MDT discussion:

*   **Pelvic progression:** Presacral mass enlarged (53x44mm) with new sacral/iliac invasion and rectal wall involvement [@2022-12-29|MR | MR].
*   **Abdominal progression:** Liver metastases increased in size/number (max 17mm); new splenic lesion suggests possible infarct [@2022-12-29|CT | CT].
*   **Assessment:** Imaging confirms disseminated recurrence (bone/liver), necessitating evaluation per recurrent disease guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
```


## pathologist

```
Opiniion on pathology and molecular findings for 2023-01-03 discussion:

- Diagnosis of Recurrent Clear Cell Carcinoma confirmed by IHC profile (HNF1B+, NapsinA+, WT1-) [@HI22-06789 | LAB].
- Molecular: HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM p.Y316C variant detected [@OH2203828 | Genomics].
- Management of recurrent disease involves stratification by histologic subtype and platinum sensitivity [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
```


## nuclear

```
Based on the provided imaging reports and guidelines:

*   MR and CT confirm progression: presacral mass, new iliac bone nodule, and increasing hepatic metastases [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].
*   No PET/CT provided; metabolic imaging could confirm viability of new bone and liver lesions if equivocal.
*   Defining recurrence extent is critical for guiding systemic therapy options and management [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
```


## MERGED SUMMARY (Assistant)

```
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months).
- **Genetics/Biomarkers:** HRD negative, BRCA/ARID1A/PIK3CA wild-type, pMMR; germline ATM variant p.Y316C.
- **Disease Status:** Disseminated recurrence includes enlarging presacral mass with distinct rectal wall invasion, increased liver metastases, and new splenic infarct.
- **Clinical Contraindications:** Anti-angiogenic therapy is contraindicated due to rectal invasion identifying high risk of GI perforation.
- **Status:** Significant anemia (Hb 74 g/L) requires immediate correction.

**Controversies:**
- None; consensus achieved to exclude anti-angiogenics from treatment plan.

**Missing Info:**
- PET/CT remains an option specifically for palliative radiation planning if anatomical imaging is insufficient to define active tumor volume.

**Working Plan:**
- Immediately correct anemia via transfusion to permit safe systemic therapy.
- Initiate non-platinum cytotoxic monotherapy (avoiding anti-angiogenics).
- Refer for palliative radiotherapy evaluation targeting progressive presacral mass and bone metastases.
- Monitor for thromboembolic complications given new splenic infarct.
```


## INTERACTION LOG (Round × Turn)

### Round 1

#### Turn 1
- **oncologist → pathologist:** Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
- **radiologist → oncologist:** Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation.
- **pathologist → oncologist:** I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].


## FINAL REFINED PLANS (per Round)

### Round 1


## chair

```
Detailed Management Plan:

*   Initiate non-platinum chemotherapy; avoid anti-angiogenics given rectal invasion risk identifying GI perforation hazard [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], [@2022-12-29|MR | MR].
*   Correct severe anemia (Hb 74 g/L) immediately to facilitate safe systemic treatment administration [@20230103|5600862 | LAB].
*   Refer for palliative radiotherapy evaluation targeting progressive presacral mass and new bone metastases [@2022-12-29|MR | MR].
```


## oncologist

```
Based on the confirmed platinum resistance, genomic profile, and risk of bowel perforation:

- Avoid anti-angiogenics due to rectal invasion; proceed with non-platinum cytotoxic monotherapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
- Correct severe anemia (HGB 74 g/L) via transfusion prior to systemic therapy initiation [@20230103|5600862 | LAB].
- Genomic profile (BRCAwt/HRDneg) and pMMR status limit targeted options; consider clinical trials [@OH2203828 | Genomics].
```


## radiologist

```
*   Rectal wall invasion [@2022-12-29|MR | MR] implies high perforation risk if anti-angiogenic therapy is considered.
*   Disseminated progression (liver, bone) [@2022-12-29|CT | CT] confirms need for systemic salvage therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
*   New splenic infarct identified [@2022-12-29|CT | CT]; monitor for thromboembolic complications.
```


## pathologist

```
Here is the final pathology assessment and plan:

- Confirmed Clear Cell Carcinoma (HNF1B+, NapsinA+) with intact MMR proteins (pMMR) ruling out MSI-H [@HI22-06789 | LAB].
- Genomic profiling shows HRD negative status, ARID1A wild-type, and germline ATM variant p.Y316C [@OH2203828 | Genomics].
- Histologic subtype and molecular profile are critical for guiding systemic therapy in recurrent disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
```


## nuclear

```
Based on the imaging findings and multidisciplinary context:

*   MR and CT confirm disseminated progression (liver, bone, presacral); metabolic confirmation is not currently required for diagnosis [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].
*   PET/CT remains an option to define active tumor volume if palliative radiation planning requires metabolic discrimination.
*   Accurate staging of recurrence is essential to guide systemic versus local therapy decisions [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
```


## RAW AGENT LOGS

### chair
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** Here is the initial MDT assessment for the visit on 2023-01-03:

*   Platinum-resistant recurrence (PFI ~2 months); recommend non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
*   Correct significant anemia (Hb 74 g/L) prior to systemic therapy initiation to ensure safety [@20230103|5600862 | LAB].
*   BRCA/HRD negative status limits targeted options; consider palliative radiation for progressive bone metastases [@OH2203828 | Genomics], [@2022-12-29 | MR].
  
  *(2026-01-21T08:02:50.635151)*

- **User:** ROLE: chair. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

Allowed targets: [oncologist,radiologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {
  "speak": "no",
  "messages": []
}
  
  *(2026-01-21T08:06:18.792101)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

[RECENT_DELTAS]
[R1T1 DELTA] oncologist->pathologist(missing): Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist->oncologist(safety): Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist->oncologist(unspecified): I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

DISCUSSION HISTORY (this round):
Turn 1: oncologist→pathologist: Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist→oncologist: Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist→oncologist: I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** Detailed Management Plan:

*   Initiate non-platinum chemotherapy; avoid anti-angiogenics given rectal invasion risk identifying GI perforation hazard [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], [@2022-12-29|MR | MR].
*   Correct severe anemia (Hb 74 g/L) immediately to facilitate safe systemic treatment administration [@20230103|5600862 | LAB].
*   Refer for palliative radiotherapy evaluation targeting progressive presacral mass and new bone metastases [@2022-12-29|MR | MR].
  
  *(2026-01-21T08:08:06.084703)*

- **User:** 
As the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.
Based on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.

# MDT DISCUSSION SUMMARY
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months).
- **Genetics/Biomarkers:** HRD negative, BRCA/ARID1A/PIK3CA wild-type, pMMR; germline ATM variant p.Y316C.
- **Disease Status:** Disseminated recurrence includes enlarging presacral mass with distinct rectal wall invasion, increased liver metastases, and new splenic infarct.
- **Clinical Contraindications:** Anti-angiogenic therapy is contraindicated due to rectal invasion identifying high risk of GI perforation.
- **Status:** Significant anemia (Hb 74 g/L) requires immediate correction.

**Controversies:**
- None; consensus achieved to exclude anti-angiogenics from treatment plan.

**Missing Info:**
- PET/CT remains an option specifically for palliative radiation planning if anatomical imaging is insufficient to define active tumor volume.

**Working Plan:**
- Immediately correct anemia via transfusion to permit safe systemic therapy.
- Initiate non-platinum cytotoxic monotherapy (avoiding anti-angiogenics).
- Refer for palliative radiotherapy evaluation targeting progressive presacral mass and bone metastases.
- Monitor for thromboembolic complications given new splenic infarct.

# INITIAL EXPERT OPINIONS
- chair: Here is the initial MDT assessment for the visit on 2023-01-03:

*   Platinum-resistant recurrence (PFI ~2 months); recommend non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial [@gu
- oncologist: Based on the recurrence timing and biomarker profile:

- Platinum-resistant recurrence (PFI <6 months) confirmed by rising CA125 933 U/ml and multi-site metastases [@20221229|9703212 | LAB].
- Genomic
- radiologist: Here are the imaging findings for the MDT discussion:

*   **Pelvic progression:** Presacral mass enlarged (53x44mm) with new sacral/iliac invasion and rectal wall involvement [@2022-12-29|MR | MR].
*
- pathologist: Opiniion on pathology and molecular findings for 2023-01-03 discussion:

- Diagnosis of Recurrent Clear Cell Carcinoma confirmed by IHC profile (HNF1B+, NapsinA+, WT1-) [@HI22-06789 | LAB].
- Molecula
- nuclear: Based on the provided imaging reports and guidelines:

*   MR and CT confirm progression: presacral mass, new iliac bone nodule, and increasing hepatic metastases [@2022-12-29|MR | MR] [@2022-12-29|CT

# DISCUSSION INTERACTIONS
Round 1: R1T1: oncologist→pathologist: Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy | R1T1: radiologist→oncologist: Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall an | R1T1: pathologist→oncologist: I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the 



# FINAL REFINED PLANS (All experts, all rounds)
{
  "Round 1": {
    "chair": "Detailed Management Plan:\n\n*   Initiate non-platinum chemotherapy; avoid anti-angiogenics given rectal invasion risk identifying GI perforation hazard [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], [@2022-12-29|MR | MR].\n*   Correct severe anemia (Hb 74 g/L) immediately to facilitate safe systemic treatment administration [@20230103|5600862 | LAB].\n*   Refer for palliative radiotherapy evaluation targeting progressive presacral mass and new bone metastases [@2022-12-29|MR | MR].",
    "oncologist": "Based on the confirmed platinum resistance, genomic profile, and risk of bowel perforation:\n\n- Avoid anti-angiogenics due to rectal invasion; proceed with non-platinum cytotoxic monotherapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Correct severe anemia (HGB 74 g/L) via transfusion prior to systemic therapy initiation [@20230103|5600862 | LAB].\n- Genomic profile (BRCAwt/HRDneg) and pMMR status limit targeted options; consider clinical trials [@OH2203828 | Genomics].",
    "radiologist": "*   Rectal wall invasion [@2022-12-29|MR | MR] implies high perforation risk if anti-angiogenic therapy is considered.\n*   Disseminated progression (liver, bone) [@2022-12-29|CT | CT] confirms need for systemic salvage therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n*   New splenic infarct identified [@2022-12-29|CT | CT]; monitor for thromboembolic complications.",
    "pathologist": "Here is the final pathology assessment and plan:\n\n- Confirmed Clear Cell Carcinoma (HNF1B+, NapsinA+) with intact MMR proteins (pMMR) ruling out MSI-H [@HI22-06789 | LAB].\n- Genomic profiling shows HRD negative status, ARID1A wild-type, and germline ATM variant p.Y316C [@OH2203828 | Genomics].\n- Histologic subtype and molecular profile are critical for guiding systemic therapy in recurrent disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].",
    "nuclear": "Based on the imaging findings and multidisciplinary context:\n\n*   MR and CT confirm disseminated progression (liver, bone, presacral); metabolic confirmation is not currently required for diagnosis [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].\n*   PET/CT remains an option to define active tumor volume if palliative radiation planning requires metabolic discrimination.\n*   Accurate staging of recurrence is essential to guide systemic versus local therapy decisions [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]."
  }
}

# CLINICAL TRIAL RECOMMENDATION (from assistant)
Trial Recommendation:
- id: 350
- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
- Reason: Patient has recurrent platinum-resistant ovarian clear cell carcinoma (a gynecologic malignancy) and has failed standard chemotherapy (1L), matching the inclusion criteria.
- Missing eligibility confirmations (0-2 items):
  - ECOG Performance Status
  - Adequate organ function (bone marrow, liver, kidney)

STRICT RULES:
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@OH2203828|2022-04-18 | Genomics], [@2022-12-29 | MR], [@2022-12-29 | CT]). Note: Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.
- If a clinical trial has been recommended by the assistant and you judge it appropriate for the patient, mention it naturally within Core Treatment Strategy or Change Triggers and cite it using [@trial | trial_id] format (e.g., [@trial | 350]).
- If experts disagree, pick the safest plan and state the key uncertainty.
- You MUST consider the MDT discussion summary and interactions above when making your decision.

# Response Format
Final Assessment:
<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>

Core Treatment Strategy:
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >

Change Triggers:
- < ≤20 words "if X, then adjust management from A to B" >
- < ≤20 words "if X, then adjust management from A to B" >

  
  **Assistant:** Final Assessment:
Platinum-resistant recurrent clear cell carcinoma (HRD-negative, pMMR) presenting with severe anemia and disseminated metastases including presacral mass with rectal invasion. Systemic therapy options are limited by platinum resistance and contraindication to anti-angiogenics due to high bowel perforation risk.

Core Treatment Strategy:
- Transfuse immediately for severe anemia (Hb 74 g/L) to permit safe systemic therapy [@20230103|5600862 | LAB].
- Initiate non-platinum chemotherapy; strictly avoid anti-angiogenics due to rectal invasion [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], [@2022-12-29|MR | MR].
- Refer for palliative radiotherapy evaluation targeting progressive presacral mass and bone metastases [@2022-12-29|MR | MR].
- Consider enrollment in Phase Ib/II trial for recurrent gynecologic malignancies as alternative to standard chemo [@trial | 350].

Change Triggers:
- If splenic infarct symptoms arise, evaluate for anticoagulation versus supportive care [@2022-12-29|CT | CT].
- If progression occurs on non-platinum regimen, transition to best supportive care or early-phase trials.
  
  *(2026-01-21T08:11:31.404103)*


### oncologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** Based on the recurrence timing and biomarker profile:

- Platinum-resistant recurrence (PFI <6 months) confirmed by rising CA125 933 U/ml and multi-site metastases [@20221229|9703212 | LAB].
- Genomic profiling indicates HRD negative and BRCA wild-type status, limiting PARP inhibitor utility [@OH2203828 | Genomics].
- Consider non-platinum chemotherapy +/- anti-angiogenics; significant anemia (HGB 74 g/L) warrants correction prior to treatment [@20230103|5600862 | LAB] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
  
  *(2026-01-21T08:03:19.911067)*

- **User:** ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

Allowed targets: [chair,radiologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {
  "speak": "yes",
  "messages": [
    {
      "target": "pathologist",
      "message": "Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].",
      "why": "missing"
    }
  ]
}
  
  *(2026-01-21T08:06:47.390622)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

[RECENT_DELTAS]
[R1T1 DELTA] oncologist->pathologist(missing): Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist->oncologist(safety): Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist->oncologist(unspecified): I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

DISCUSSION HISTORY (this round):
Turn 1: oncologist→pathologist: Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist→oncologist: Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist→oncologist: I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** Based on the confirmed platinum resistance, genomic profile, and risk of bowel perforation:

- Avoid anti-angiogenics due to rectal invasion; proceed with non-platinum cytotoxic monotherapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
- Correct severe anemia (HGB 74 g/L) via transfusion prior to systemic therapy initiation [@20230103|5600862 | LAB].
- Genomic profile (BRCAwt/HRDneg) and pMMR status limit targeted options; consider clinical trials [@OH2203828 | Genomics].
  
  *(2026-01-21T08:08:35.725196)*


### radiologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** Here are the imaging findings for the MDT discussion:

*   **Pelvic progression:** Presacral mass enlarged (53x44mm) with new sacral/iliac invasion and rectal wall involvement [@2022-12-29|MR | MR].
*   **Abdominal progression:** Liver metastases increased in size/number (max 17mm); new splenic lesion suggests possible infarct [@2022-12-29|CT | CT].
*   **Assessment:** Imaging confirms disseminated recurrence (bone/liver), necessitating evaluation per recurrent disease guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
  
  *(2026-01-21T08:03:46.791618)*

- **User:** ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

Allowed targets: [chair,oncologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {
  "speak": "yes",
  "messages": [
    {
      "target": "oncologist",
      "message": "Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation.",
      "why": "safety"
    }
  ]
}
  
  *(2026-01-21T08:07:05.673279)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

[RECENT_DELTAS]
[R1T1 DELTA] oncologist->pathologist(missing): Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist->oncologist(safety): Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist->oncologist(unspecified): I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

DISCUSSION HISTORY (this round):
Turn 1: oncologist→pathologist: Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist→oncologist: Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist→oncologist: I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** *   Rectal wall invasion [@2022-12-29|MR | MR] implies high perforation risk if anti-angiogenic therapy is considered.
*   Disseminated progression (liver, bone) [@2022-12-29|CT | CT] confirms need for systemic salvage therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
*   New splenic infarct identified [@2022-12-29|CT | CT]; monitor for thromboembolic complications.
  
  *(2026-01-21T08:08:57.985080)*


### pathologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** Opiniion on pathology and molecular findings for 2023-01-03 discussion:

- Diagnosis of Recurrent Clear Cell Carcinoma confirmed by IHC profile (HNF1B+, NapsinA+, WT1-) [@HI22-06789 | LAB].
- Molecular: HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM p.Y316C variant detected [@OH2203828 | Genomics].
- Management of recurrent disease involves stratification by histologic subtype and platinum sensitivity [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
  
  *(2026-01-21T08:04:26.648335)*

- **User:** ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

Allowed targets: [chair,oncologist,radiologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {
  "speak": "yes",
  "messages": [
    {
      "target": "oncologist",
      "message": "I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].",
      "why": "new-critical"
    }
  ]
}
  
  *(2026-01-21T08:07:30.143175)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

[RECENT_DELTAS]
[R1T1 DELTA] oncologist->pathologist(missing): Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist->oncologist(safety): Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist->oncologist(unspecified): I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

DISCUSSION HISTORY (this round):
Turn 1: oncologist→pathologist: Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist→oncologist: Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist→oncologist: I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** Here is the final pathology assessment and plan:

- Confirmed Clear Cell Carcinoma (HNF1B+, NapsinA+) with intact MMR proteins (pMMR) ruling out MSI-H [@HI22-06789 | LAB].
- Genomic profiling shows HRD negative status, ARID1A wild-type, and germline ATM variant p.Y316C [@OH2203828 | Genomics].
- Histologic subtype and molecular profile are critical for guiding systemic therapy in recurrent disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
  
  *(2026-01-21T08:09:21.361898)*


### nuclear
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** Based on the provided imaging reports and guidelines:

*   MR and CT confirm progression: presacral mass, new iliac bone nodule, and increasing hepatic metastases [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].
*   No PET/CT provided; metabolic imaging could confirm viability of new bone and liver lesions if equivocal.
*   Defining recurrence extent is critical for guiding systemic therapy options and management [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
  
  *(2026-01-21T08:05:29.524178)*

- **User:** ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

Allowed targets: [chair,oncologist,radiologist,pathologist]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"no","messages":[]}
  
  *(2026-01-21T08:07:43.065437)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

[RECENT_DELTAS]
[R1T1 DELTA] oncologist->pathologist(missing): Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist->oncologist(safety): Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist->oncologist(unspecified): I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

DISCUSSION HISTORY (this round):
Turn 1: oncologist→pathologist: Please confirm if mismatch repair (MMR) or MSI status was assessed, as this determines immunotherapy eligibility in platinum-resistant recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | radiologist→oncologist: Caution regarding proposed anti-angiogenics: MRI demonstrates tumor invasion into the rectal wall and sacrum [@2022-12-29|MR | MR], which significantly increases the risk of GI perforation. | pathologist→oncologist: I confirm the tumor is pMMR (MLH1/MSH2/MSH6/PMS2 intact) and HNF1B/NapsinA positive, supporting the Clear Cell diagnosis and ruling out MSI-H status [@HI22-06789 | LAB].

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** Based on the imaging findings and multidisciplinary context:

*   MR and CT confirm disseminated progression (liver, bone, presacral); metabolic confirmation is not currently required for diagnosis [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].
*   PET/CT remains an option to define active tumor volume if palliative radiation planning requires metabolic discrimination.
*   Accurate staging of recurrence is essential to guide systemic versus local therapy decisions [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
  
  *(2026-01-21T08:09:42.865626)*


### assistant
- **User:** Summarize expert opinions concisely for MDT.
{"chair":"Here is the initial MDT assessment for the visit on 2023-01-03:\n\n*   Platinum-resistant recurrence (PFI ~2 months); recommend non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n*   Correct significant anemia (Hb 74 g/L) prior to systemic therapy initiation to ensure safety [@20230103|5600862 | LAB].\n*   BRCA/HRD negative status limits targeted options; consider palliative radiation for progressive bone metastases [@OH2203828 | Genomics], [@2022-12-29 | MR].","oncologist":"Based on the recurrence timing and biomarker profile:\n\n- Platinum-resistant recurrence (PFI <6 months) confirmed by rising CA125 933 U/ml and multi-site metastases [@20221229|9703212 | LAB].\n- Genomic profiling indicates HRD negative and BRCA wild-type status, limiting PARP inhibitor utility [@OH2203828 | Genomics].\n- Consider non-platinum chemotherapy +/- anti-angiogenics; significant anemia (HGB 74 g/L) warrants correction prior to treatment [@20230103|5600862 | LAB] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].","radiologist":"Here are the imaging findings for the MDT discussion:\n\n*   **Pelvic progression:** Presacral mass enlarged (53x44mm) with new sacral/iliac invasion and rectal wall involvement [@2022-12-29|MR | MR].\n*   **Abdominal progression:** Liver metastases increased in size/number (max 17mm); new splenic lesion suggests possible infarct [@2022-12-29|CT | CT].\n*   **Assessment:** Imaging confirms disseminated recurrence (bone/liver), necessitating evaluation per recurrent disease guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].","pathologist":"Opiniion on pathology and molecular findings for 2023-01-03 discussion:\n\n- Diagnosis of Recurrent Clear Cell Carcinoma confirmed by IHC profile (HNF1B+, NapsinA+, WT1-) [@HI22-06789 | LAB].\n- Molecular: HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM p.Y316C variant detected [@OH2203828 | Genomics].\n- Management of recurrent disease involves stratification by histologic subtype and platinum sensitivity [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].","nuclear":"Based on the provided imaging reports and guidelines:\n\n*   MR and CT confirm progression: presacral mass, new iliac bone nodule, and increasing hepatic metastases [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].\n*   No PET/CT provided; metabolic imaging could confirm viability of new bone and liver lesions if equivocal.\n*   Defining recurrence extent is critical for guiding systemic therapy options and management [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]."}

Output:
Key Knowledge:
- ...
Controversies:
- ...
Missing Info:
- ...
Working Plan:
- ...
  
  **Assistant:** **Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.
  
  *(2026-01-21T08:05:52.263884)*

- **User:** You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.

CURRENT_MDT_GLOBAL_KNOWLEDGE:
[MDT_GLOBAL_KNOWLEDGE]
**Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months, CA125 933 U/ml).
- **Genetics:** HRD negative, BRCA/ARID1A/PIK3CA wild-type; germline ATM variant detected.
- **Disease Status:** Disseminated recurrence confirmed by imaging; includes enlarging presacral mass (sacral/rectal invasion), increased liver metastases, and new splenic lesion.
- **Complications:** Significant anemia (Hb 74 g/L) requiring correction.

**Controversies:**
- None identified; consensus exists regarding platinum resistance and disease progression.

**Missing Info:**
- PET/CT metabolic assessment (noted by Nuclear Medicine as potentially useful to confirm viability if anatomical imaging is equivocal).

**Working Plan:**
- Correct anemia prior to initiating systemic therapy.
- Consider non-platinum chemotherapy +/- anti-angiogenic agent or clinical trial enrollment (limited targeted options due to biomarker profile).
- Evaluate determining feasibility of palliative radiation for presacral/bone metastases.

ROUND_1_FINAL_PLANS_JSON:
{"chair":"Detailed Management Plan:\n\n*   Initiate non-platinum chemotherapy; avoid anti-angiogenics given rectal invasion risk identifying GI perforation hazard [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22], [@2022-12-29|MR | MR].\n*   Correct severe anemia (Hb 74 g/L) immediately to facilitate safe systemic treatment administration [@20230103|5600862 | LAB].\n*   Refer for palliative radiotherapy evaluation targeting progressive presacral mass and new bone metastases [@2022-12-29|MR | MR].","oncologist":"Based on the confirmed platinum resistance, genomic profile, and risk of bowel perforation:\n\n- Avoid anti-angiogenics due to rectal invasion; proceed with non-platinum cytotoxic monotherapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n- Correct severe anemia (HGB 74 g/L) via transfusion prior to systemic therapy initiation [@20230103|5600862 | LAB].\n- Genomic profile (BRCAwt/HRDneg) and pMMR status limit targeted options; consider clinical trials [@OH2203828 | Genomics].","radiologist":"*   Rectal wall invasion [@2022-12-29|MR | MR] implies high perforation risk if anti-angiogenic therapy is considered.\n*   Disseminated progression (liver, bone) [@2022-12-29|CT | CT] confirms need for systemic salvage therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].\n*   New splenic infarct identified [@2022-12-29|CT | CT]; monitor for thromboembolic complications.","pathologist":"Here is the final pathology assessment and plan:\n\n- Confirmed Clear Cell Carcinoma (HNF1B+, NapsinA+) with intact MMR proteins (pMMR) ruling out MSI-H [@HI22-06789 | LAB].\n- Genomic profiling shows HRD negative status, ARID1A wild-type, and germline ATM variant p.Y316C [@OH2203828 | Genomics].\n- Histologic subtype and molecular profile are critical for guiding systemic therapy in recurrent disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].","nuclear":"Based on the imaging findings and multidisciplinary context:\n\n*   MR and CT confirm disseminated progression (liver, bone, presacral); metabolic confirmation is not currently required for diagnosis [@2022-12-29|MR | MR] [@2022-12-29|CT | CT].\n*   PET/CT remains an option to define active tumor volume if palliative radiation planning requires metabolic discrimination.\n*   Accurate staging of recurrence is essential to guide systemic versus local therapy decisions [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]."}
  
  **Assistant:** **Key Knowledge:**
- **Diagnosis:** Platinum-resistant recurrent Clear Cell Carcinoma (PFI ~2 months).
- **Genetics/Biomarkers:** HRD negative, BRCA/ARID1A/PIK3CA wild-type, pMMR; germline ATM variant p.Y316C.
- **Disease Status:** Disseminated recurrence includes enlarging presacral mass with distinct rectal wall invasion, increased liver metastases, and new splenic infarct.
- **Clinical Contraindications:** Anti-angiogenic therapy is contraindicated due to rectal invasion identifying high risk of GI perforation.
- **Status:** Significant anemia (Hb 74 g/L) requires immediate correction.

**Controversies:**
- None; consensus achieved to exclude anti-angiogenics from treatment plan.

**Missing Info:**
- PET/CT remains an option specifically for palliative radiation planning if anatomical imaging is insufficient to define active tumor volume.

**Working Plan:**
- Immediately correct anemia via transfusion to permit safe systemic therapy.
- Initiate non-platinum cytotoxic monotherapy (avoiding anti-angiogenics).
- Refer for palliative radiotherapy evaluation targeting progressive presacral mass and bone metastases.
- Monitor for thromboembolic complications given new splenic infarct.
  
  *(2026-01-21T08:10:11.848027)*


### trial_selector
- **User:** You are an MDT assistant for gynecologic oncology clinical trial matching.

CRITICAL BEHAVIOR:
- You MUST NOT ask the user any questions.
- You MUST NOT request additional information.
- You MUST NOT output anything except the required template.
- Use ONLY the provided PATIENT CASE text and AVAILABLE TRIALS list.
- If eligibility is unclear due to missing key facts, you MUST output None.

PATIENT CASE (facts only; do not infer):
# ORIGINAL CASE JSON
{"CASE_CORE":{"ADJUVANT_TREATMENT":{"cycles_or_courses":"6","given":"Yes","regimens":["白紫+卡铂"]},"BIOMARKERS":{"AFP":"<0.91 ng/ml (2022-10-12)","CA125":"933.00 U/ml (2022-12-29)","HER2":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","TMB":"Unknown"},"BRCA1":"Unknown","BRCA2":"Unknown","CURRENT_STATUS":"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging","DIAGNOSIS":{"components":["High-grade adenocarcinoma involving full-thickness intestinal wall","Lymph node metastasis (4/15)","Peritoneal/rectal/vaginal involvement described"],"histology":"透明细胞癌; 肠壁全层见高级别腺癌","laterality":"Unknown","primary":"卵巢癌复发","site":"Ovary"},"HRD":"Unknown","INITIAL_TREATMENT":"Unknown","LINE_OF_THERAPY":[{"cycles":"6","end_date":"2022-08-17","intent":"Unknown","line":"1L","regimen":"白紫+卡铂","start_date":"Unknown"}],"MAINTENANCE":"Unknown","MAINTENANCE_DETAIL":{"end_date":"Unknown","given":"Unknown","regimens":[],"start_date":"Unknown"},"NEOADJUVANT":"Unknown","PFI_days":"56","PLATINUM_HISTORY":[{"PFI_days":"56","end_date":"2022-08-17","evidence":"Rise in CA125/CA19-9 on 2022-10-12","evidence_type":"Biochemical","first_relapse_date":"2022-10-12","line":"1L","start_date":"Unknown","status":"Resistant"}],"PLATINUM_PFI_CURRENT":"56","PLATINUM_STATUS":"Resistant","PLATINUM_STATUS_CURRENT":"Resistant","RELAPSE":"Yes","RELAPSE_DATE":{"date":"2022-10-12","evidence":"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence","type":"Biochemical"},"SCENE":"Platinum_resistant_relapse","STAGE":{"stage_basis":"Unknown","stage_system":"Unknown","stage_text":"Unknown"},"SURGERY_DONE":{"date":"2022-03-28","performed":"Yes","procedure":"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair"},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]},"VISIT_DATE":"2023-01-03","first_relapse_date":"2022-10-12","last_platinum_end_date":"2022-08-17"},"LAB_TRENDS":{"labs":[{"analyte":"CA125","history":[{"date":"2022-08-15","flag":"Unknown","value":"14.90"},{"date":"2022-10-12","flag":"↑","value":"89.60"},{"date":"2022-11-17","flag":"↑","value":"403"},{"date":"2022-12-29","flag":"↑","value":"933.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"933.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"CA19-9","history":[{"date":"2022-08-15","flag":"Unknown","value":"7.16"},{"date":"2022-10-12","flag":"↑","value":"77.20"},{"date":"2022-12-29","flag":"↑","value":"229.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"229.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"HE4","history":[{"date":"2022-08-15","flag":"↑","value":"87.90"},{"date":"2022-10-12","flag":"Unknown","value":"59.70"},{"date":"2022-12-29","flag":"↑","value":"111.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"111.00"},"reference_range":"Unknown","unit":"pmol/L"},{"analyte":"AFP","history":[{"date":"2022-10-12","flag":"Unknown","value":"<0.91"}],"latest":{"date":"2022-10-12","flag":"Unknown","value":"<0.91"},"reference_range":"Unknown","unit":"ng/ml"}],"milestones":[{"date":"2022-03-28","description":"Primary cytoreductive surgery performed","type":"Surgery"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂","type":"ChemoEnd"},{"date":"2022-10-12","description":"Biochemical relapse with rising tumor markers","type":"Relapse"}]},"MED_ONC":{"current_regimen":{"cycle_info":"6 cycles of 白紫+卡铂, last 2022-08-17","last_admin_date":"2022-08-17","name":"Unknown"},"genetic_testing":{"germline":[],"somatic":[]},"monitoring_points":[],"planned_next_regimen":"Unknown","prior_systemic_therapies":["白紫+卡铂"]},"NUC_MED":{"studies":[]},"PATHOLOGY":{"specimens":[{"components":["Tumor size ~7x4x2.5 cm","Bilateral margins negative","Pericolic lymph nodes 4/15 positive","One tumor nodule (posterior bladder)"],"date":"2022-03-28","diagnosis":"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma","grade":"High-grade","ihc":[{"marker":"MLH1","result":"+"},{"marker":"MSH6","result":"+"},{"marker":"MSH2","result":"+"},{"marker":"PMS2","result":"+"},{"marker":"ER","result":"partial+"},{"marker":"PR","result":"few weak+"},{"marker":"P53","result":"+/-"},{"marker":"WT1","result":"-"},{"marker":"Ki-67","result":"60%+"},{"marker":"HNF1B","result":"+"},{"marker":"NapsinA","result":"focal+"},{"marker":"P16","result":"+"},{"marker":"PAX8","result":"+"},{"marker":"SALL4","result":"-"},{"marker":"ZBTB16","result":"-"}],"involvement_sites":["Rectosigmoid colon","Left retroperitoneum","Vagina","Pericolic lymph nodes","Posterior bladder nodule"],"laterality":"Unknown","molecular":[],"raw_text":"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）","sample_type":"Surgical resection","site":"Partial rectosigmoid + left retroperitoneal tumor + partial vagina","tumor_size":"7 x 4 x 2.5 cm","uncertainty_or_missing":["BRCA/HRD testing not reported"]}]},"RADIOLOGY":{"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"},"studies":[{"anatomic_sites":["Pelvis"],"date":"2022-10-24","findings":["Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules"],"impression":"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases","modality":"MRI","trend_vs_prior":"Unknown"},{"anatomic_sites":["Liver"],"date":"2022-10-25","findings":["Multiple intrahepatic nodules, some new compared to prior"],"impression":"Probable metastases in liver","modality":"CT","trend_vs_prior":"Worse"},{"anatomic_sites":["Pelvis; sacrum; right iliac bone"],"date":"2022-12-30","findings":["Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar"],"impression":"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible","modality":"MRI","trend_vs_prior":"Worse"},{"anatomic_sites":["Liver; spleen"],"date":"2022-12-30","findings":["Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct"],"impression":"Progression of hepatic metastases","modality":"CT","trend_vs_prior":"Worse"}]},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]}}

# MUTATION / GENETIC REPORTS (Full Text for Trial Matching)
⚠️ COMPREHENSIVE NGS PANEL (~20,000 genes) - INTERPRETATION RULES:
• '未检出' (not detected) = NO pathogenic mutation found
• '（视为阴性）' (considered negative) = NO pathogenic mutation found
• '阴性' (negative) = negative result
• Genes with specific variants (e.g., 'NM_xxx:exon:c.xxx:p.xxx') = POSITIVE mutation
• If a gene is NOT mentioned, it means NO pathogenic mutation (comprehensive panel)

## Mutation Report 1 (ID: OH2203828, Date: 2022-04-18)
ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）


AVAILABLE TRIALS (compact; use id/name exactly as shown):
[
  {
    "id": "345",
    "name": " 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "2、3、4L",
    "biomarker": null,
    "doctor": "李佳佳",
    "sponsor": "江苏康宁杰瑞生物制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、HER2 表达（IHC≥1+）\n\n2、经标准治疗失败、不能耐受标准治疗\n\n或缺乏有效治疗手段的受试者；",
    "key_exclusion": "",
    "contacts": [
      "王 涛"
    ],
    "phones": [
      "18721569326"
    ],
    "_raw": {
      "id": "345",
      "项目名称": " 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
      "医生": "李佳佳",
      "试验治疗/用药": "JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "II期",
      "申请单位": "江苏康宁杰瑞生物制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2、3、4L",
      "入组排除标准": "1、HER2 表达（IHC≥1+）<br />\r\n2、经标准治疗失败、不能耐受标准治疗<br />\r\n或缺乏有效治疗手段的受试者；<br />",
      "联系人": [
        "王 涛"
      ],
      "联系电话": [
        "18721569326"
      ]
    }
  },
  {
    "id": "346",
    "name": "一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "朱 俊",
    "sponsor": "阿斯利康投资（中国）有限公司",
    "lead_or_participation": "牵头",
    "treatment": "Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）\n\n2、经标准治疗失败、不能耐受标准治疗\n\n或缺乏有效治疗手段的受试者；",
    "key_exclusion": "",
    "contacts": [
      "江文燕"
    ],
    "phones": [
      "15664735519"
    ],
    "_raw": {
      "id": "346",
      "项目名称": "一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)",
      "医生": "朱 俊",
      "试验治疗/用药": "Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "II期",
      "申请单位": "阿斯利康投资（中国）有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）<br />\r\n2、经标准治疗失败、不能耐受标准治疗<br />\r\n或缺乏有效治疗手段的受试者；<br />",
      "联系人": [
        "江文燕"
      ],
      "联系电话": [
        "15664735519"
      ]
    }
  },
  {
    "id": "348",
    "name": "一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究",
    "phase": "I期",
    "conditions": null,
    "line_of_therapy": "2L、3L",
    "biomarker": null,
    "doctor": "郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳",
    "sponsor": " 上海美雅珂生物技术有限责任公司",
    "lead_or_participation": "牵头",
    "treatment": "MRG004A（ADC，靶向组织因子（tissue factor，TF））",
    "key_inclusion": "1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。",
    "key_exclusion": "",
    "contacts": [
      "杨 珂"
    ],
    "phones": [
      "17774582517"
    ],
    "_raw": {
      "id": "348",
      "项目名称": "一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究",
      "医生": "郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳",
      "试验治疗/用药": "MRG004A（ADC，靶向组织因子（tissue factor，TF））",
      "期别": "I期",
      "申请单位": " 上海美雅珂生物技术有限责任公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2L、3L",
      "入组排除标准": "1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。",
      "联系人": [
        "杨 珂"
      ],
      "联系电话": [
        "17774582517"
      ]
    }
  },
  {
    "id": "350",
    "name": "评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究",
    "phase": "Ⅰb/Ⅱ 期",
    "conditions": null,
    "line_of_therapy": "2L、3L",
    "biomarker": null,
    "doctor": "吴 勇、刘汝娇 、高水平",
    "sponsor": "成都百利多特生物药业有限责任公司",
    "lead_or_participation": "牵头",
    "treatment": "单臂研究\n\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤",
    "key_exclusion": "",
    "contacts": [
      "李 想"
    ],
    "phones": [
      "17703993082"
    ],
    "_raw": {
      "id": "350",
      "项目名称": "评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究",
      "医生": "吴 勇、刘汝娇 、高水平",
      "试验治疗/用药": "单臂研究<br />\r\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）<br />",
      "期别": "Ⅰb/Ⅱ 期",
      "申请单位": "成都百利多特生物药业有限责任公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2L、3L",
      "入组排除标准": "1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤",
      "联系人": [
        "李 想"
      ],
      "联系电话": [
        "17703993082"
      ]
    }
  },
  {
    "id": "351",
    "name": " 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "李佳佳、刘汝娇",
    "sponsor": "西藏海思科制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）",
    "key_inclusion": "既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；",
    "key_exclusion": "",
    "contacts": [
      "张倩野"
    ],
    "phones": [
      "18627004197"
    ],
    "_raw": {
      "id": "351",
      "项目名称": " 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究",
      "医生": "李佳佳、刘汝娇",
      "试验治疗/用药": "HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）",
      "期别": "Ⅰ期",
      "申请单位": "西藏海思科制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；",
      "联系人": [
        "张倩野"
      ],
      "联系电话": [
        "18627004197"
      ]
    }
  },
  {
    "id": "353",
    "name": "在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "刘汝娇",
    "sponsor": " 石药集团中奇制药技术（石家庄）有限公司",
    "lead_or_participation": "参与（天津市肿瘤医院 郝继辉）",
    "treatment": "注射用西罗莫司（白蛋白结合型）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "刘 涵"
    ],
    "phones": [
      "19109628595"
    ],
    "_raw": {
      "id": "353",
      "项目名称": "在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究",
      "医生": "刘汝娇",
      "试验治疗/用药": "注射用西罗莫司（白蛋白结合型）",
      "期别": "Ⅰ期",
      "申请单位": " 石药集团中奇制药技术（石家庄）有限公司",
      "牵头/参与": "参与（天津市肿瘤医院 郝继辉）",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者",
      "联系人": [
        "刘 涵"
      ],
      "联系电话": [
        "19109628595"
      ]
    }
  },
  {
    "id": "354",
    "name": "一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "吴 勇",
    "sponsor": " 浙江道尔生物科技有限公司",
    "lead_or_participation": "参与（组长单位：上海市肺科医院）",
    "treatment": "注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）",
    "key_inclusion": "1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗\n\n2、HPV 16+",
    "key_exclusion": "",
    "contacts": [
      "浦东/郭 伟 、徐汇/江文艳"
    ],
    "phones": [
      "13156793722、15664735519"
    ],
    "_raw": {
      "id": "354",
      "项目名称": "一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究",
      "医生": "吴 勇",
      "试验治疗/用药": "注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）",
      "期别": "Ⅰ期",
      "申请单位": " 浙江道尔生物科技有限公司",
      "牵头/参与": "参与（组长单位：上海市肺科医院）",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗<br />\r\n2、HPV 16+<br />",
      "联系人": [
        "浦东/郭 伟 、徐汇/江文艳"
      ],
      "联系电话": [
        "13156793722、15664735519"
      ]
    }
  },
  {
    "id": "358",
    "name": "评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "2-3线",
    "biomarker": null,
    "doctor": "张 剑 、李佳佳",
    "sponsor": "江苏康宁杰瑞生物制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "徐汇/牛紫嫣 浦东/刘雅琦"
    ],
    "phones": [
      "15638299516 18636833967 "
    ],
    "_raw": {
      "id": "358",
      "项目名称": "评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
      "医生": "张 剑 、李佳佳",
      "试验治疗/用药": "JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）",
      "期别": "Ⅰ期",
      "申请单位": "江苏康宁杰瑞生物制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2-3线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者",
      "联系人": [
        "徐汇/牛紫嫣 浦东/刘雅琦"
      ],
      "联系电话": [
        "15638299516 18636833967 "
      ]
    }
  },
  {
    "id": "359",
    "name": "SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": ">2L",
    "biomarker": null,
    "doctor": "张 剑 、李佳佳 、刘汝娇、 高水平",
    "sponsor": "苏州盛迪亚生物医药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、组织学确诊的子宫颈癌；\n\n2、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "黄洋洋"
    ],
    "phones": [
      "13226861415"
    ],
    "_raw": {
      "id": "359",
      "项目名称": "SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究",
      "医生": "张 剑 、李佳佳 、刘汝娇、 高水平",
      "试验治疗/用药": "SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "Ⅰ期",
      "申请单位": "苏州盛迪亚生物医药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": ">2L",
      "入组排除标准": "1、组织学确诊的子宫颈癌；<br />\r\n2、标准治疗失败或无标准治疗患者<br />",
      "联系人": [
        "黄洋洋"
      ],
      "联系电话": [
        "13226861415"
      ]
    }
  },
  {
    "id": "361",
    "name": "一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "李佳佳",
    "sponsor": "Bayer Consumer Care AG",
    "lead_or_participation": "参与",
    "treatment": "单臂研究\n\nBAY 2927088（TKI，靶向HER2）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者；\n\n2、HER2激活突变（本院或认证的机构）；\n\n3、需提供肿瘤组织切片。",
    "key_exclusion": "",
    "contacts": [
      "李金山"
    ],
    "phones": [
      "18893190113 "
    ],
    "_raw": {
      "id": "361",
      "项目名称": "一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究",
      "医生": "李佳佳",
      "试验治疗/用药": "单臂研究<br />\r\nBAY 2927088（TKI，靶向HER2）<br />",
      "期别": "II期",
      "申请单位": "Bayer Consumer Care AG",
      "牵头/参与": "参与",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者；<br />\r\n2、HER2激活突变（本院或认证的机构）；<br />\r\n3、需提供肿瘤组织切片。<br />",
      "联系人": [
        "李金山"
      ],
      "联系电话": [
        "18893190113 "
      ]
    }
  }
]

DECISION RULE (be conservative):
Recommend ONE trial ONLY IF ALL are true:
1) Cancer type / primary site clearly matches.
2) Disease setting clearly matches (e.g., recurrent/advanced/metastatic and line is not fundamentally unclear).
3) Required biomarker/subtype is explicitly present in case text (if trial requires it).
4) No more than 2 critical eligibility confirmations remain.

If ANY of the above is not satisfied -> output None.

OUTPUT TEMPLATE (EXACT; no extra text):

Trial Recommendation:
- id: <trial id or None>
- name: <trial name or None>
- Reason: <1 short sentence>
- Missing eligibility confirmations (0-2 items):
  - item1 (or "None")
  - item2
  
  **Assistant:** Trial Recommendation:
- id: 350
- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
- Reason: Patient has recurrent platinum-resistant ovarian clear cell carcinoma (a gynecologic malignancy) and has failed standard chemotherapy (1L), matching the inclusion criteria.
- Missing eligibility confirmations (0-2 items):
  - ECOG Performance Status
  - Adequate organ function (bone marrow, liver, kidney)
  
  *(2026-01-21T08:10:53.938026)*

